Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 0,23 € (+163,46 %). La mediana es de 0,23 € (+163,46 %).
| Comprar |
5 |
| Mantener |
5 |
| Vender |
1 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Applied Therapeutics delisted from Nasdaq after takeover by Cycle Group
Applied Therapeutics has completed its merger with Cycle Group Holdings and is now an indirect wholly owned subsidiary of Cycle Group. Cycle Group subsidiary AT2B acquired all outstanding shares for $0.088 per share; shareholders also received a non-tradable CVR with potential payments of up to $0.40. Applied filed to suspend trading, delist and deregister with the SEC; the board and several executives resigned, and James Harrison took over leadership. Cycle is integrating the lead drug candidate Govorestat into its portfolio; analysts sharply cut ratings and price targets for Applied stock following the transaction. » Más en de.investing.com
Cycle extends takeover offer for Applied Therapeutics
Cycle Group Holdings has extended the deadline for its takeover offer for Applied Therapeutics to 11:59 p.m. ET on January 29, 2026. Cycle is offering $0.088 per share in cash plus a non-tradable contingent value right; the price is close to the stock’s 52-week low. The board of directors of Applied Therapeutics unanimously recommends tendering the shares and warns that, if tendering is insufficient, liquidation and the immediate repayment of an $8.5 million promissory note to Cycle would likely follow. Financial data show a weak financial picture with negative EBITDA and significant financial challenges for Applied Therapeutics. » Más en de.investing.com
Applied Therapeutics explores strategic alternatives and cuts 46% of workforce
Applied Therapeutics has launched a process to evaluate strategic options such as M&A, partnerships and licensing agreements to maximize shareholder value. At the same time, the company is reducing costs by cutting 46% of its workforce; it did not disclose exact employee numbers. The stock fell sharply last year and the company reported a negative EBITDA of USD 99.61 million, but says it has more cash than debt. Applied Therapeutics is reviewing FDA Type C meeting minutes for its lead candidate govorestat and considering next steps, after also agreeing a $75 million share sale facility with Cantor Fitzgerald. » Más en de.investing.com
Applied Therapeutics stock plunges after uncertainty in FDA approval process for Govorestat
Applied Therapeutics shares fell about 55% in pre-market trading after the company said the next steps for a Govorestat approval filing, including a potential accelerated submission, have not been determined. Applied is waiting for the official FDA meeting minutes to decide how to proceed; it had previously aimed for a submission in Q3 2025. Govorestat is being developed to treat the rare neuropathy CMT‑SORD and already has multiple regulatory special designations in the US and Europe. » Más en de.investing.com
FDA discussion on Govorestat sends Applied Therapeutics stock sharply higher
Applied Therapeutics completed a meeting with the FDA about a potential regulatory filing for Govorestat to treat CMT‑SORD. The stock jumped sharply after investors learned of the discussion; the company is now waiting for the official meeting minutes before determining next steps. Govorestat has orphan drug status from the FDA and EMA and is also being developed for other rare diseases. Applied Therapeutics has also entered an agreement for an at‑the‑market equity offering of up to USD 75 million to raise capital. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | septiembre de 2025 | YoY |
|---|---|---|
| Ingresos | 852,13 mil | - |
| Beneficio bruto | 852,13 mil | - |
| Beneficio neto | -16,18 M | - |
| EBITDA | -16,09 M | - |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 13,5 M € |
Número de acciones | 144,3 M |
Máximo/mínimo de 52 semanas | 1,36 € - 0,0818 € |
| Dividendos | No |
Beta | 2,08 |
Ratio P/E | -0,37 |
Ratio PEG | 0,00 |
Ratio P/B | -26,72 |
Ratio P/S | 14,86 |
Perfil de la empresa
Applied Therapeutics, Inc., una empresa biofarmacéutica en fase clínica, desarrolla productos novedosos dirigidos a la enfermedad cardiovascular, la galactosemia y las complicaciones diabéticas. Su principal candidato a producto es AT-007, que ha completado la fase 1/2 para el tratamiento de la galactosemia en voluntarios sanos y adultos, y que se encuentra en un estudio clínico pediátrico para el tratamiento de la galactosemia en niños; para el tratamiento de la deficiencia de sorbitol deshidrogenasa; y para el tratamiento de la enzima fosfomannomutasa CDG. La empresa también desarrolla AT-001, que se encuentra en ensayos clínicos de fase III para el tratamiento de la miocardiopatía diabética, así como para el tratamiento de la neuropatía periférica diabética. Sus productos en fase preclínica incluyen AT-003 para el tratamiento de la retinopatía diabética; AT-104, un inhibidor de PI3K para el tratamiento de la leucemia linfoblástica aguda de células T, una neoplasia hematológica huérfana. Applied Therapeutics, Inc. se constituyó en 2016 y tiene su sede en Nueva York, Nueva York.
| Nombre | Applied Therapeutics |
| CEO | Les D. Funtleyder |
| Sede | New York City,
ny Estados Unidos |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 14/05/2019 |
| Empleados | 35 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | APLT |
Frankfurt | 2UV.F |
Düsseldorf | 2UV.DU |
München | 2UV.MU |